Faeth Therapeutics
NASDAQ: FTHAustin, US · Delaware corporation · 11 known investors
Faeth Therapeutics is a biotechnology company developing therapies that target multiple nodes of a biological pathway at once rather than a single node. Its lead program is PIKTOR; the company was acquired by Sensei Biotherapeutics in February 2026 in a deal that included a $200 million private placement.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
AP
Anand ParikhCo-founder
OM
Oliver MaddocksCo-founder
Board
AM
JD
Jayson DallasBoard director
RG
Robert GouldBoard director
SH
Stephen HahnBoard director
Investors · 11
Able PartnersNew York City · $500K – $3M
Atacama VenturesSan Francisco
Cota CapitalSan Francisco
Future VenturesLos Altos · $1M – $10M
iSelect FundSt. Louis · $250K – $2M
S2G InvestmentsChicago · $1M – $5M
AgFunderreportedSan Francisco · $10K – $5M
Cantos VenturesreportedSan Francisco · $400K – $1.5M
Digitalis VenturesreportedNew York · $100K – $10M
KdT VenturesreportedAustin · $500K – $3M
Khosla VenturesreportedMenlo Park · $5K – $50Mvia Alex Morgan · board
Reported raises · per SEC filings
Form D private placements$24.4M disclosed across 1 round · 2025
▶$24.4MraisedJan 2026 · 35 investors · BiotechnologyRule 506(b)
▶$24.4MraisedJan 2026 · 35 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jayson DallasDirector
- Anand ParikhExecutive Officer, Director, Promoter
- Alex MorganDirector
- Robert GouldDirector
- Stephen HahnDirector
- Oliver MaddocksExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $24.4M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapFate Therapeutics20 shared keywordsFate Therapeutics develops clinical-stage cell therapy drug candidates for autoimmune diseases and cancer, using an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products. Its therapies aim to overcome manufacturing and commercialization limitations of conventional cell therapies.
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Faeth Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Faeth Therapeutics do?
- Faeth Therapeutics is a biotechnology company developing therapies that target multiple nodes of a biological pathway at once rather than a single node. Its lead program is PIKTOR; the company was acquired by Sensei Biotherapeutics in February 2026 in a deal that included a $200 million private placement.
- Who founded Faeth Therapeutics?
- Faeth Therapeutics was founded by Anand Parikh, Oliver Maddocks.
- Who are Faeth Therapeutics's investors?
- Faeth Therapeutics's investors include Able Partners, Atacama Ventures, Cota Capital, Future Ventures, iSelect Fund, S2G Investments, AgFunder, Cantos Ventures and 3 more.
- How much funding has Faeth Therapeutics raised?
- Faeth Therapeutics has disclosed $24.4M raised across 1 round.
- Where is Faeth Therapeutics headquartered?
- Faeth Therapeutics is headquartered in Austin, US.